REGULATORY STRATEGY FOR REGISTRATION OF COMBINATION PRODUCTS TO US-FDA
Journal Title: International Journal of Drug Regulatory Affairs - Year 2014, Vol 2, Issue 3
Abstract
In pharmaceutical industry all the healthcare products are categorized into Drugs, Devices, and biologics and they are regulated by their respective departments of the regulatory authorities. Due to more and more development of science and technology in the current scenario, had led to the invention of innovative novel products in healthcare system for better diagnosis and treatment of diseases, advancement of these novel technologies have led to a the blurring of historical lines of separation between the healthcare products, so these advances had led to the existence of combination products. Combination products raise a variety of regulatory and review challenges compared with single-entity products. They have the potential to provide enhanced therapeutic advantages. It ranges in complexity from Drug-eluting stents to gene therapy systems and from chemotherapeutic Drugs combined with monoclonal antibodies to novel nanotechnology-based Drug delivery systems. They include innovative products for diagnostic and therapeutic treatments of cardiovascular, metabolic, and oncologic disorders, among other types of products. In this article we describe the regulations for registration of combination products in US and their regulatory considerations for identification, jurisdiction and review, premarket activities, applicability of Good Manufacturing Practices (GMPs) and post marketed requirements, adverse event reporting, inspection and enforcement.
Authors and Affiliations
Kotha Vihar, Elphine Prabahar, Rama Rao Nadendla, Desu Bhrama Srinivasarao
Keywords
Related Articles
- EP ID EP349828
- DOI 10.22270/ijdra.v2i3.139
- Views 101
- Downloads 0
Current Regulatory requirements for Registration of Nutraceuticals in India and USA
There is growing recognition of the potential role for nutraceuticals and dietary supplements in helping to reduce health risks and improve health quality. Pharmaceutical and nutritional companies are aware of the moneta...
A review on ANDA submission requirements for Generic drugs: “Paragraph IV certification” as per FDA CDER guidelines
USFDA is one the most regulated agencies wherein the submission process is most critical. The study depends on how to submit ANDA application as per FDA, CDER guidelines in paragraph IV submission in Federal Food, Drug,...
Integrating PLCM strategy in Pharmaceutical Emerging Market
All products and services must denote definite life cycles. The life cycle talks about the period from the product‘s first launch till it wind-up onto the market. Throughout this age noteworthy modifications are made in...
NUTRACEUTICALS - A REGULATORY REVIEW
The Nutraceuticals are the emerging sector in the Pharma Industry. As people are more and more concerned about their health and diseases caused by the malnutrition, the growth of the Nutraceuticals worldwide are inevitab...
DMF FILING IN US, EUROPE AND CANADA
A Drug Master File or DMF is a reference source that provides drug evaluator’s confidential information not available to drug product manufacturer about the specific process and components used in the manufacturing, proc...